Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management

Autor: Hai-Yong Chen, Yibin Feng, Cheng Zhang, Ning Wang, Sha Li, Guoyi Tang
Rok vydání: 2021
Předmět:
LOX1
lectin-like oxidized LDL receptor 1

BUN
blood urea nitrogen

TGBM
thickness of glomerular basement membrane

NQO1
NAD(P)H:quinone oxidoreductase 1

STAT
signal transducers and activators of transcription

N/O
not observed

p62
sequestosome 1 protein

p-IRS1
phospho-IRS1

Review
NOX-4
nicotinamide adenine dinucleotide phosphate-oxidase-4

OCP
oxidative carbonyl protein

Traditional Chinese medicine
AGEs
advanced glycation end-products

N/A
not applicable

TRAF5
tumor-necrosis factor receptor-associated factor 5

Health problems
0302 clinical medicine
ESRD
end-stage renal disease

LDL
low-density lipoprotein

BMP-7
bone morphogenetic protein-7

TGFβR-I/II
TGF-β receptor I/II

Medicine
P70S6K
70-kDa ribosomal protein S6 kinase

General Pharmacology
Toxicology and Pharmaceutics

SOCS
suppressor of cytokine signaling proteins

HO-1
heme oxygenase-1

0303 health sciences
TG
triglyceride

BW
body weight

HDL-C
high density lipoprotein-cholesterol

RASI
renin-angiotensin system inhibitor

ATK
protein kinase B

TBARS
thiobarbituric acid-reactive substance

BCL-XL
B-cell lymphoma-extra large

Gαq
Gq protein alpha subunit

GCK
glucokinase

PI3K
phosphatidylinositol 3 kinases

Systematic review
TLR-2/4
toll-like receptor 2/4

IR
insulin receptor

PERK
protein kinase RNA-like eukaryotic initiation factor 2A kinase

030220 oncology & carcinogenesis
CRP
C-reactive protein

IRS
insulin receptor substrate

AM
mesangial area

JAK
Janus kinase

FBG
fasting blood glucose

ETAR
endothelium A receptor

LDL-C
low density lipoprotein-cholesterol

CD2AP
CD2-associated protein

eIF2α
eukaryotic initiation factor 2α

RM1-950
mTOR
mammalian target of rapamycin

CHOP
C/EBP homologous protein

STZ
streptozotocin

03 medical and health sciences
ADE
adverse event

PKC
protein kinase C

LC3
microtubule-associated protein light chain 3

ORP150
150-kDa oxygen-regulated protein

PGE2
prostaglandin E2

IL-1β/6
interleukin 1β/6

Diabetic kidney disease
IGF-1
insulin-like growth factor 1

EP
E-prostanoid receptor

FN
fibronectin

eGFR
estimated GFR

MDA
malondialdehyde

Chinese medicine
MMP-2
matrix metallopeptidase 2

XBP-1
spliced X box-binding protein 1

TGF-β
tumor growth factor β

GRB 10
growth factor receptor-bound protein 10

medicine.disease
Clinical trial
GRP78
glucose-regulated protein 78

UP
urinary protein

IGF-1R
insulin-like growth factor 1 receptor

ACEI
angiotensin-converting enzyme inhibitor

BCL-2
B-cell lymphoma 2

EMT
epithelial-to-mesenchymal transition

MAPK
mitogen-activated protein kinase

MYD88
myeloid differentiation primary response 88

PBG
postprandial blood glucose

RCT
randomized clinical trial

N/R
not reported

COL-I/IV
collagen I/IV

PINK1
PTEN-induced putative kinase 1

UACR
urinary albumin to creatinine ratio

C
control group

Diabetic nephropathy
GPX
glutathione peroxidase

ICAM-1
intercellular adhesion molecule-1

Bioinformatics
VCAM-1
vascular cell adhesion molecule-1

AMPKα
adenosine monophosphate-activated protein kinase α

DM
diabetes mellitus

TFEB
transcription factor EB

TNF-α
tumor necrosis factor α

Molecular target
IKK-β
IκB kinase β

Signaling pathway
GLUT4
glucose transporter type 4

BAX
BCL-2-associated X protein

NF-κB
nuclear factor kappa-light-chain-enhancer of activated B cells

PARP
poly(ADP-Ribose) polymerase

SMURF-2
SMAD ubiquitination regulatory factor 2

AREs
antioxidant response elements

MD
mean difference

SMAD
small mothers against decapentaplegic

MCP-1
monocyte chemotactic protein-1

VEGF
vascular endothelial growth factor

cAMP
cyclic adenosine monophosphate

ARB
angiotensin receptor blocker

PAI-1
plasminogen activator inhibitor-1

SMD
standard mean difference

JNK
c-Jun N-terminal kinase

NRF2
nuclear factor erythroid 2-related factor 2

IκB-α
inhibitory protein α

Herbal medicine
TCM
traditional Chinese medicine

DG
glomerular diameter

GSK-3
glycogen synthase kinase 3

SIRT1
sirtuin 1

D
duration

HbA1c
glycosylated hemoglobin

WMD
weight mean difference

CTGF
connective tissue growth factor

ER
endoplasmic reticulum

DN
diabetic nephropathy

ROS
reactive oxygen species

CCR
creatinine clearance rate

SOD
superoxide dismutase

Diabetes mellitus
PGC-1α
peroxisome proliferator-activated receptor gamma coactivator 1α

ET-1
endothelin-1

UMA
urinary microalbumin

SCr
serum creatinine

IRE-1α
inositol-requiring enzyme-1α

030304 developmental biology
TII
tubulointerstitial injury index

RAGE
receptors of AGE

business.industry
GFR
glomerular filtration rate

PTEN
phosphatase and tensin homolog

CI
confidence interval

TC
total cholesterol

SD-rat
Sprague–Dawley rat

UAER
urinary albumin excretion rate

DKD
diabetic kidney disease

T
treatment group

Molecular targets
Therapeutics. Pharmacology
α-SMA
α smooth muscle actin

SD
standard deviation

business
DAG
diacylglycerol

GCLC
glutamate-cysteine ligase catalytic subunit

Kidney disease
Zdroj: Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica B, Vol 11, Iss 9, Pp 2749-2767 (2021)
ISSN: 2211-3835
DOI: 10.1016/j.apsb.2020.12.020
Popis: Diabetic nephropathy (DN) has been recognized as a severe complication of diabetes mellitus and a dominant pathogeny of end-stage kidney disease, which causes serious health problems and great financial burden to human society worldwide. Conventional strategies, such as renin-angiotensin-aldosterone system blockade, blood glucose level control, and bodyweight reduction, may not achieve satisfactory outcomes in many clinical practices for DN management. Notably, due to the multi-target function, Chinese medicine possesses promising clinical benefits as primary or alternative therapies for DN treatment. Increasing studies have emphasized identifying bioactive compounds and molecular mechanisms of reno-protective effects of Chinese medicines. Signaling pathways involved in glucose/lipid metabolism regulation, antioxidation, anti-inflammation, anti-fibrosis, and podocyte protection have been identified as crucial mechanisms of action. Herein, we summarize the clinical efficacies of Chinese medicines and their bioactive components in treating and managing DN after reviewing the results demonstrated in clinical trials, systematic reviews, and meta-analyses, with a thorough discussion on the relative underlying mechanisms and molecular targets reported in animal and cellular experiments. We aim to provide comprehensive insights into the protective effects of Chinese medicines against DN.
Graphical abstract Diabetic nephropathy is one of the most severe complications of diabetes mellitus. Chinese medicines have been intensively studied in treating diabetic nephropathy. This review comprehensively summarizes and discusses the clinical efficacies and underlying mechanisms of Chinese medicines for diabetic nephropathy, providing deep insights and profound perspectives into this field.Image 1
Databáze: OpenAIRE